The abstract is read at the publisher; the summary is JClub's.
Three months of DOAC therapy after TAVR reduced hypoattenuated leaflet thickening (HALT) at 3 months versus lifelong single antiplatelet therapy, 12.1% vs 31.8%.
- Why it matters: HALT is common after transcatheter aortic valve replacement and may be linked to thromboembolic events, leaving uncertainty about optimal prevention strategies.
- What they did: In NOTION-4, 352 patients without an oral anticoagulation indication were randomized to lifelong SAPT or DOAC for 3 months then SAPT, with HALT assessed by cardiac CT at 12 months.
- The result: HALT at 1 year was 32.2% with SAPT and 28.3% with DOAC-3m (P=0.54), while the composite of death, stroke, or major/life-threatening bleeding was 2.3% vs 8.2% at 12 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.